EpiVax is organizing their 3rd annual Immunogenicity and Tolerance Seminar on 9th of November, 2017.
Location: Hilton Apollolaan, Apollolaan 138, Amsterdam.
This meeting will focus on the determinants of immunogenicity – a key feature of effective vaccines and a key barrier to success in the clinic for protein therapeutics. Conversely, tolerance induction is a key feature of successful protein therapeutics, while suppressing immune responses to vaccines. The reduction of T cell epitopes and introduction of Treg epitopes (like Tregitopes) for protein therapeutics, and the reverse process for vaccines, will be discussed and illustrated in case studies.
Enjoy engaging presentations, case studies and discussions with speakers to include Dr. Annie De Groot, MD (EpiVax CEO), Marieke van Ham, PhD (Sanquin), Wim Jiskoot, PhD (Leiden University Medical Center), Vincent Lombardi, PhD (Stallergenes), Ab Osterhaus, PhD (University of Veterinary Medicine in Hannover, Germany), Bram Slütter, PhD (Leiden University) and Jagadeesh Bayry (Institut National de la Santé et de la Recherche Médicale (INSERM) Unité). Food, refreshments and cocktail hour to conclude. Register today to reserve your seat, and discover the positive reputation of our seminar:
“Good combination of talks about determinants of immunogenicity and tolerance. Very well hosted by Annie; made good connections between people in audience Good networking possibilities”
“Wide variety of topics related to immunogenicity, it forces us to go outside of our usual domain of expertise.”